A computational method for predicting the most likely evolutionary trajectories in the step-wise accumulation of resistance mutations.
P. falciparum
evolutionary biology
infectious disease
microbiology
Journal
eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614
Informations de publication
Date de publication:
22 Dec 2023
22 Dec 2023
Historique:
received:
07
11
2022
accepted:
21
12
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
aheadofprint
Résumé
Pathogen evolution of drug resistance often occurs in a stepwise manner via the accumulation of multiple mutations that in combination have a non-additive impact on fitness, a phenomenon known as epistasis. The evolution of resistance via the accumulation of point mutations in the DHFR genes of Plasmodium falciparum (Pf ) and Plasmodium vivax (Pv) has been studied extensively and multiple studies have shown epistatic interactions between these mutations determine the accessible evolutionary trajectories to highly resistant multiple mutations. Here, we simulated these evolutionary trajectories using a model of molecular evolution, parameterized using Rosetta Flex ddG predictions, where selection acts to reduce the target-drug binding affinity. We observe strong agreement with pathways determined using experimentally measured IC50 values of pyrimethamine binding, which suggests binding affinity is strongly predictive of resistance and epistasis in binding affinity strongly influences the order of fixation of resistance mutations. We also infer pathways directly from the frequency of mutations found in isolate data, and observe remarkable agreement with the most likely pathways predicted by our mechanistic model, as well as those determined experimentally. This suggests mutation frequency data can be used to intuitively infer evolutionary pathways, provided sufficient sampling of the population.
Identifiants
pubmed: 38132182
doi: 10.7554/eLife.84756
pii: 84756
doi:
pii:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MR/T000171/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R025576/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R020973/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T000171/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M01360X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N010469/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R025576/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R020973/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T000171/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R013063/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M01360X/1
Pays : United Kingdom
Informations de copyright
© 2023, Eccleston et al.
Déclaration de conflit d'intérêts
RE, EM, SC, TC, NF The authors declare that no competing interests exist.